Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 9/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21680695 | 1.00 | SCN9A (0.35) | SCN9AFPR2SYKSIRT6PIK3CA | |
| SCHEMBL30669758 | 1.00 | SCN9A (0.35) | SCN9AFPR2SYKSIRT6PIK3CA | |
| SCHEMBL17374001 | 0.83 | SYK (0.38) | SCN9AFPR2SYKSIRT6PIK3CA | |
| SCHEMBL30627275 | 0.80 | KAT2B (0.37) | — | |
| SCHEMBL15110157 | 0.80 | KAT2B (0.37) | — | |
| SCHEMBL27039743 | 0.79 | ALDH1A1 (0.41) | — | |
| SCHEMBL27039744 | 0.79 | ALDH1A1 (0.41) | — | |
| SCHEMBL31661104 | 0.79 | ALDH1A1 (0.41) | — | |
| SCHEMBL31291010 | 0.76 | SCN9A (0.39) | SCN9AFPR2SYK | |
| SCHEMBL27039419 | 0.76 | SCN9A (0.39) | SCN9AFPR2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-112566915-B | Thiadiazole IRAK4 inhibitors | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-112533924-B | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11053250-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3837259-A1 | PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES AS IRAK4 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3837261-A1 | THIADIAZOLE IRAK4 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112566915-A | Thiadiazole IRAK4 inhibitor | 吉利德科学公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112533924-A | Pyrrolo [1,2-b ] pyridazine derivatives as IRAK4 inhibitors | 吉利德科学公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-12 | — | — | US | disclosed |
| WO-2020036830-A1 | PYRROLO[1,2-B]PYRIDAZINE DERIVATIVES AS IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | SCN9A 3941/4885FPR2 2014/4885SYK 1498/4885 |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SCN9A 3832/4885FPR2 3429/4885SYK 39/4885 |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SCN9A 3832/4885FPR2 3429/4885SYK 39/4885 |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | IRAK4, IRAK3, IRAK2 | SCN9A 3974/4885FPR2 3001/4885SYK 51/4885 |
| US-11053250-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | SCN9A 3941/4885FPR2 2014/4885SYK 1498/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SCN9A 3832/4885FPR2 3429/4885SYK 39/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SCN9A 3832/4885FPR2 3429/4885SYK 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.